Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Canine obesity: an overview.

J Gossellin1, J A Wren, S J Sunderland

  • 1Pfizer Ltd, Veterinary Medicine Research and Development, Sandwich, Kent, UK. jacques.gossellin@pfizer.com

Journal of Veterinary Pharmacology and Therapeutics
|August 1, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The bright optical flash and afterglow from the gamma-ray burst GRB 130427A.

Science (New York, N.Y.)·2013
Same author

Short communication: survey of fresh cow management practices of dairy cattle on small and large commercial farms.

Journal of dairy science·2010
Same author

Dirlotapide: a review of its properties and role in the management of obesity in dogs.

Journal of veterinary pharmacology and therapeutics·2007
Same author

Biologic activity of dirlotapide, a novel microsomal triglyceride transfer protein inhibitor, for weight loss in obese dogs.

Journal of veterinary pharmacology and therapeutics·2007
Same author

The safety of dirlotapide in dogs.

Journal of veterinary pharmacology and therapeutics·2007
Same author

Evaluation of dirlotapide for sustained weight loss in overweight Labrador retrievers.

Journal of veterinary pharmacology and therapeutics·2007
Same journal

What Do We Know About Cyclooxygenases Expression in the Lower Urinary Tract of Dogs and Cats? A Systematic Review.

Journal of veterinary pharmacology and therapeutics·2026
Same journal

Pharmacokinetics of Orally Administered Clonidine in Dogs.

Journal of veterinary pharmacology and therapeutics·2026
Same journal

Veterinary Pharmaceutical Safety Competencies for New Graduates: Description of an Interprofessional Simulated Learning Activity.

Journal of veterinary pharmacology and therapeutics·2026
Same journal

Characterization of the Pharmacokinetics and Physiological Effects of Tapentadol in Horses.

Journal of veterinary pharmacology and therapeutics·2026
Same journal

A Visual Analogue Scale Exercise for Teaching Antimicrobial Selection in Veterinary Pharmacology: Tool Development and Initial Implementation.

Journal of veterinary pharmacology and therapeutics·2026
Same journal

Supplement: 16th International Congress of the European Association for Veterinary Pharmacology and Toxicology, Thessaloniki, Greece, June 28-July 1, 2026.

Journal of veterinary pharmacology and therapeutics·2026
See all related articles

Obesity affects 20-40% of dogs and can lead to serious health issues. A new medication, dirlotapide, offers a way to help dogs lose weight without diet or exercise changes, improving owner compliance.

Area of Science:

  • Veterinary Medicine
  • Canine Health
  • Pharmacology

Background:

  • Canine obesity is prevalent, affecting 20-40% of dogs, and is linked to numerous health problems.
  • Traditional weight management strategies (diet, exercise) are challenging due to owner compliance issues.
  • Existing human medications for weight loss are unsuitable for canine use.

Purpose of the Study:

  • To introduce a novel therapeutic approach for canine weight reduction.
  • To evaluate the efficacy of dirlotapide as an adjunct to traditional weight management.
  • To assess the impact of the new therapy on owner compliance and long-term success.

Main Methods:

  • Introduction of microsomal triglyceride transfer protein inhibitors for canine use.
  • Utilizing dirlotapide as a therapeutic option for canine weight management.

Related Experiment Videos

  • Augmenting traditional weight control programs with pharmacological intervention.

    • Main Results:

    • Dirlotapide facilitates weight loss without requiring dietary restriction or exercise modification.
    • The novel approach simplifies weight management for owners, potentially increasing compliance.
    • This method offers a new tool for veterinarians to combat canine obesity.

    Conclusions:

    • Microsomal triglyceride transfer protein inhibitors, like dirlotapide, represent a significant advancement in veterinary weight management.
    • Pharmacological intervention can effectively support and enhance traditional methods for treating canine obesity.
    • The ease of use and effectiveness of dirlotapide may improve long-term weight control success in dogs.